SecurityINNV / Innovus Pharmaceuticals, Inc. (45778V106)
IndustryPharmaceutical Preparations
Institutional Owners0
Common Shares Outstanding207,169,412 shares (as of 2018-06-30)

Institutional Stock Ownership and Shareholders

Innovus Pharmaceuticals, Inc. (OTC:INNV) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include .
Innovus Pharmaceuticals, Inc. (OTC:INNV) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Prev Value
Current Value

Related News Stories

SeeThruEquity Issues Update on Innovus Pharmaceuticals (INNV) and Raises Target Price to $0.75

2018-08-21 accesswire
NEW YORK, NY / ACCESSWIRE / August 21, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update on Innovus Pharmaceuticals, Inc. (OTCQB: INNV) and has raised its target price to $0.75.

Innovus Pharmaceuticals, Inc. (INNV) CEO Bassam Damaj on Q2 2018 Results - Earnings Call Transcript

2018-08-15 seekingalpha
Good day and welcome to the Innovus Second Quarter 2018 earnings conference call. [Operator Instructions] Please note that this event is recorded.

Your Daily Pharma Scoop: Amicus Cleared, Gemphire Tumbles, ASLAN Proceeds

2018-08-13 seekingalpha
Discussion: Amicus Therapeutics' (FOLD) Galafold (migalastat) for the treatment of adult patients with Fabry disease is now FDA-approved. Migalastat as a monotherapy is already approved in EU and other geographies and has moved to commercialization stage. Almost negligible gross income in 2016 (<$1M) has zoomed to $63.61M over the last financial, indicating a 290.59% revenue growth. (16-2)

Innovus Pharmaceuticals' (INNV) CEO Bassam Damaj on Q1 2018 Results - Earnings Call Transcript

2018-05-15 seekingalpha
Good afternoon and thank you, everyone, for joining us today. My name is Steven and I am assisting the company with its Investor Relations Call. (1-1)

CUSIP: 45778V106